CLLS241115P7500
- 6.25
- 0.000.00%
Cellectis Newsroom
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $6
Cellectis Is Maintained at Overweight by Barclays
Cellectis Analyst Ratings
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Cuts Target Price to $5
Cellectis SA: Strong Buy Rating on Robust Pipeline and Financial Stability
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $7
Cellectis Analyst Ratings
Oppenheimer Trims Cellectis Price Target to $10 From $11, Maintains Outperform Rating
J.P. Morgan Securities Co., Ltd.: The Cellectis (CLLS.US) rating was reaffirmed and adjusted from superior to superior market rating, and the target price was adjusted from $6.00 to $6.00.
Cellectis Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Barclays Remains a Buy on Cellectis SA (CLLS)
Cellectis SA: A Hold Rating Amidst Strategic Partnerships and Pipeline Potential
Hold Rating for Cellectis SA: A Balance of Promising Data and Pending Uncertainties
Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)